Harpoon Therapeutics — Corporate Update (June 2021)
50 slides from Harpoon Therapeutics's corporate update, Jun 4, 2021
Slide 1: Spearheading Immunotherapies Pipeline Update
Spearheading Immunotherapies PIPELINE UPDATE June 4, 2021 Exhibit 99.3
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing fut
Slide 3: Presentation Agenda
Presentation Agenda Corporate Overview Highlights from HPN424 ASCO Presentation Corporate Pipeline Update HPN424 HPN536 HPN217 HPN328 ProTriTAC Scientific Update Program Status Review and 2021 Milestones
Slide 4: Corporate Overview
Corporate Overview CONFIDENTIAL
Slide 5: Broad Pipeline of Immuno-Oncology Programs
Product Candidate Target / Indication Stage of Development Anticipated 2021 Milestones Preclinical Phase 1 Phase 2 HPN424 PSMA / Prostate cancer Data presentation 1H Initiate expansion cohort Mid Year HPN536 MSLN / Ovarian, pancreatic and other solid tumors Data presentation at a medical conference
Slide 6: Broad Pipeline of T cell Engagers Advancing to Treat Multiple Cancers
Broad Pipeline of T cell Engagers Advancing to Treat Multiple Cancers Four TriTACs in clinical development poised to advance into Phase 2 expansion studies Dose-escalations reveal target engagement and T cell activation in all programs All studies are implementing step dosing to maximize high drug e
Slide 7: HPN424 ASCO Data Highlights
HPN424 ASCO Data Highlights Zs ; CONFIDENTIAL
Slide 8: HPN424 Trial Design and Status
HPN424 Trial Design and Status Dose Escalation: Single Patient Fixed Dose Escalation: 3 + 3 (3 – 6 pts per dose level) Part 1 – Dose Escalation 20 pts treated at RP2D determined in Part 1 Target Population Disease progression on the prior systemic regimen At least two prior systemic therapies approv
Slide 9: Baseline Demographics
Baseline Demographics Heterogeneous patient population, heavily pre-treated Prior Therapies n (%) Median (Range) All Prior Therapy 89 (100%) 5 (1 – 12) Novel Hormonal Therapy 87 (98%) 2 (0 – 4) Chemotherapy (mCRPC) 65 (73%) 1 (0 - 3) Immunotherapy 30 (33%) 0 (0 – 3) Age (Years) Median 70 Range 43 -
Slide 10: Common Treatment-Emergent Adverse Events by Grade
Common Treatment-Emergent Adverse Events by Grade All Grade 3 CRS events occurred with administration of 1st target dose Event, n (%) All Grades Grade 3+ Cytokine-Related AEsa Cytokine Release Syndrome (CRS)b 61 (69%) 4 (4%) Chills 60 (67%) 0 (0%) Pyrexia 58 (65%) 2 (2%) Hypotension 35 (39%) 6 (7%)
Slide 11: Time on Treatment for Target Doses <120ng/kg
Time on Treatment for Target Doses <120ng/kg Fifteen of 74 (20%) patients have remained on treatment > 24 weeks Data from clinical database as of April 23, 2021 Weeks * Step dose cohort
Slide 12: Time on Treatment for Target Doses >150ng/kg
Time on Treatment for Target Doses >150ng/kg Confirmed PR per RECIST observed at 160ng/kg Data from clinical database as of April 23, 2021
Slide 13: Focus on Chemo-Naïve Patients
Focus on Chemo-Naïve Patients Median of 5 prior regimens; median baseline PSA of 84ng/mL Eight of 17 (47%) chemo-naïve patients in castrate-resistant with at least 6 months of follow-up have remained on treatment beyond 24 weeks 6 of 20 (30%) patients with >1 post-baseline PSA value showed PSA decli
Slide 14: PSA Changes
PSA Changes Fifteen of 74 (20%) pts with >1 post-baseline value had PSA decreases from baseline ranging from -2% to -76%, including 4 pts with PSA50 response and 2 pts with PSA30 response Data from clinical database as of April 23, 2021
Slide 15: Circulating Tumor Cells (CTCs)
Circulating Tumor Cells (CTCs) Reduction in CTCs was seen in 36 of 64 (56%) patients with available baseline and on-treatment CTC counts; 14 patients had CTC0 response At Week 13, 15 of 28 (54%) patients had >30% CTC reduction from baseline, including 5 CTC0 responses; 4 of 5 CTC0 responses observed
Slide 16: Patient Profile – Patient 057
Patient 057, a 75-year old male, diagnosed January 2002 Initiated HPN424 at 160ng/kg Demonstrated RECIST partial response (-32%) at 1st post-baseline scan (Week 9), confirmed PR (-43%) at Week 18, response maintained at Week 36 Remains on study after 41 weeks of treatment HPN424-1001 Phase I Dose Es
Slide 17: Patient Profile – Patient 054
HPN424-1001 Phase I Dose Escalation Patient Profile – Patient 054 – Ongoing Patient 054, a 66-year old male, diagnosed August 2014 Initiated HPN424 at 96ng/kg and escalated to 120ng/kg in Cycle 4 Demonstrated a steady PSA decline over course of treatment, currently -60% PSA decline from baseline Sta
Slide 18: Patient Profile – Patient 064
HPN424-1001 Phase I Dose Escalation Patient Profile – Patient 064 – Ongoing Patient 064, a 71-year old male, diagnosed October 2006 Initiated HPN424 at 160ng/kg Received cabazitaxel as most recent prior therapy, progressed after 9 weeks Remains on study after 35 weeks of treatment Baseline Character
Slide 19: Pipeline Update
Pipeline Update CONFIDENTIAL
Slide 20: HPN424
HPN424 HARPOON
Slide 21: HPN424 Update
HPN424 Update Durability and PSA declines observed at higher doses Target Dose (ng/kg) 225* 300* PSA↓ CTC0 150 160 * Intended Target Dose after initiation of Prime Dose(s); patients in 300 cohort treated with different step regimens a Unconfirmed Week 24 PR Preliminary data as of May 31, 2021 120 96
Slide 22: HPN424-1001 Phase I Dose Escalation Summary
HPN424-1001 Phase I Dose Escalation Summary HPN424, a novel half-life extended PSMA-targeting T cell engager, is active and generally well tolerated CRS has been transient and manageable with 4% of patients experiencing Grade 3 CRS, no Grade 4 or 5 CRS and transaminitis events observed most often in
Slide 23: HPN536
HPN536 HARPOON
Slide 24: HPN536 Phase 1/2a Study Design
HPN536 Phase 1/2a Study Design Target population (dose escalation) Platinum refractory or platinum resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer Unresectable, locally advanced or metastatic pancreatic adenocarcinoma progressing on or after frontline treatment Malignant p
Slide 25: HPN536 Dose Cohort Enrollment
HPN536 Dose Cohort Enrollment Target Dose Total 6 1 18 1 54 1 68 6 90 7 120 6 160 3 210 5 280 5 560 5 600 6 900 6 1200 8 Total 60 MTD not identified DLTs: CRS (n=1), increased ALT (n=1) Target doses up to 1200ng/kg have been tested Data from clinical database as of May 31 , 2021
Slide 26: Platinum Relapsed/Refractory Ovarian Cancer
Platinum Relapsed/Refractory Ovarian Cancer Five of 27 (19%) evaluable pts remained on study > 24 weeks Target Dose (ng/kg) Data from clinical database as of May 31, 2021 Time on Treatment Week 24 6 18 54 68 90 120 160 210 280 560 600* 900* 1200* * Intended target dose after initiation of prime dose
Slide 27: HPN536 Ovarian Cancer Anti-Tumor Activity
HPN536 Ovarian Cancer Anti-Tumor Activity Target Lesion Reductions Observed Data from clinical database as of May 31, 2021 % Change in Sum of Target Lesions Post-Baseline * Patient remains on study * 11/20 (55%) of evaluable patients have shown stability of target lesions
Slide 28: HPN536 Pharmacokinetic Data
Dose proportional increase in Cmax and exposure (AUC): all fixed dose cohorts, first priming dose and target dose of step dose cohorts Mean T1/2: 71+/-30 hrs Median T1/2: 68 hrs (14 – 181 hrs) Linear kinetics: T1/2, clearance rate, and volume of distribution are independent of dose HPN536 Pharmacoki
Slide 29: HPN217
HPN217 HARPOON
Slide 30: HPN217 Phase 1/2 Study Design
HPN217 - Phase 1/2 Study Design Target population Relapsed/Refractory Multiple Myeloma (R/R MM) Disease progression on the prior systemic regimen At least three prior therapies including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody Trial objectives Assess safety and t
Slide 31: HPN217 Dose Cohort Enrollment
HPN217 Dose Cohort Enrollment Once weekly administration tolerated, no DLTs observed to date Low grade adverse events observed, including CRS, triggered 3+3 dose escalation in cohort 6 Rapid dose escalation >400-fold increase in 12 months Cohort Dose (µg) N 1 5 1 2 15 1 3 30 2 4 90 1 5 270 2 6 810 4
Slide 32: HPN217 Pharmacokinetic Data Summary
HPN217 Pharmacokinetic Data Summary Cycle 1 Day 1 Detectable drug at the end of the dosing interval for patient at the lowest dose group (5 µg/week) Cmax and AUC appears to increase linearly with dose HPN217 half-life ranged from 43.6 to 90.7 hours at doses 270 to 1620 µg/week Mean (SD) Data as of M
Slide 33: HPN328
HPN328 HARPOON
Slide 34: HPN328 Phase 1/2 Study Design
HPN328 Phase 1/2 Study Design Dose Escalation: Single Patient Fixed Dosing Dose Escalation: 3 + 3 (3 – 6 pts per cohort) Step dosing implemented at this point Part 1 – Dose Escalation Part 2 – Dose Expansion Up to 27 patients with relapsed SCLC at the recommended phase 2 dose Simon 2-Stage Design ³
Slide 35: HPN328 Dose Cohort Enrollment
HPN328 Dose Cohort Enrollment Dose escalation progressing with single-patient cohorts Once weekly administration tolerated, no DLTs observed to date >25 fold increase in five months Cohort Dose (µg) N 1 15 1 2 45 1 3 135 1 4 405 1 Total 4 Data from clinical database as of May 10, 2021
Slide 36: SCLC Patient Profile
SCLC Patient Profile – Pt 102 – Ongoing 38% tumor reduction at Week 9, unconfirmed PR Patient 102, a 71-year old female, diagnosed in September 2020 with small cell lung cancer Initiated HPN328 at 45µg Demonstrated 38% reduction at Week 9, unconfirmed PR No treatment-related AEs observed to-date Dat
Slide 37: HPN328 Pharmacokinetic Data
HPN328 Pharmacokinetic Data Half-life extension observed: ~70 hours Increased serum Cmax with dose escalation vertical dotted line = dosing day
Slide 38: HPN328 Preliminary Flow Analysis Indicates T Cell Activation
HPN328 Preliminary Flow Analysis Indicates in vivo T Cell Activation Dose-dependent, transient peripheral T-cell margination T cell activation in 135 µg/week cohort, support in vivo T cell activation T Cell Margination Activation Marker Induction
Slide 39: HPN328 Opportunity for DLL3 Targeting Therapy
HPN328 Opportunity for DLL3 Targeting Therapy for Neuroendocrine Tumors DLL3 expression is also detected in melanoma, glioblastoma, and prostate cancer DLL3 has been identified as a therapeutic target for NEPC DLL3 protein expression detected ~76% of NEPC biopsy samples (36 of 47) In vivo anti-tumor
Slide 40: Clinical Pipeline Update Summary
Clinical Pipeline Update Summary HPN424: PSMA for prostate cancer Antitumor activity including a confirmed RECIST partial response, PSA declines and CTC reductions Treatment duration > 24 weeks observed in 15 of 74 (20%) pts CRS has been transient and manageable with 4% of patients experiencing Grad
Slide 41: ProTriTAC Scientific Update
ProTriTAC Scientific Update
Slide 42: ProTriTAC Is Designed to Expand Tumor Target Space
ProTriTAC Is Designed to Expand Tumor Target Space and Is Based on Clinically Validated TriTAC Components αALB αTarget αCD3 TriTAC ProTriTAC protease linker (red) masking moiety from αALB (orange) αALB αTarget αCD3 Started with TriTAC components Rearranged binders Added protease linker and masking m
Slide 43: ProTriTAC Expands Therapeutic Index
ProTriTAC Expands Therapeutic Index by Improving the Tumor Specificity of T Cell Engagers αALB αTarget αCD3 Long-lived prodrug Rapid clearance in circulation TUMOR CIRCULATION CIRCULATION Activation by tumor proteases & T cell-directed killing Albumin Platform: Therapeutic index expansion demonstrat
Slide 44: The EPCAM Targeting ProTriTAC HPN601
EpCAM: overexpressed in almost all adenocarcinoma and neuroendocrine tumors (ca. 350k patient deaths/year in the US) Systemic delivery (solitomab) limited by on-target toxicity, but some clinical activity observed Local delivery (catumaxomab) approved for malignant ascites, but does not address majo
Slide 45: HPN601 Has Demonstrated Expanded Therapeutic Index In Vivo
HPN601 Has Demonstrated Expanded Therapeutic Index In Vivo Compared to Constitutively Active T Cell Engagers Better Efficacy in Mouse Better Safety in Cyno Control TriTAC ProTriTAC (HPN601) Both TriTAC and ProTriTAC dosed at 100 µg/kg Peak Cytokine Levels Both TriTAC and ProTriTAC dosed at 30 µg/kg
Slide 46: Program Status Review and 2021 Milestones
Program Status Review and 2021 Milestones
Slide 47: Pipeline Next Steps
Pipeline Next Steps HPN424: PSMA for prostate cancer Complete dose selection and finalize target patient population for Phase 2 expansion cohort initiation HPN536: MSLN for ovarian, pancreatic and mesothelioma Continue dose escalation and further enrich study with mesothelioma patients HPN217: BCMA
Slide 48: Milestone Timing
Milestone Timing HPN424: Phase 1/2a data presentation H1 2021 HPN424: Initiate expansion cohort Mid year 2021 HPN424: Initial data from expansion cohort EOY 2021 HPN536: Phase 1/2a data presentation H2 2021 HPN536: Initiate expansion cohort EOY 2021 HPN217: Phase 1/2 data presentation H2 2021 HPN217
Slide 49: Broad Pipeline of T cell Engagers Advancing to Treat Multiple Cancers
Broad Pipeline of T cell Engagers Advancing to Treat Multiple Cancers Four TriTACs in clinical development poised to advance into Phase 2 expansion studies Dose-escalations reveal target engagement and T cell activation in all programs All studies are implementing step dosing to maximize high drug e
Slide 50: Spearheading Immunotherapies Pipeline Update
Spearheading Immunotherapies PIPELINE UPDATE June 4, 2021